SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Outcome Of The Board Meeting Of The Company Held Today
Outcome of the Board Meeting of the Company held today28-05-2019
28-05-2019
Looking beyond generic, Sun Pharma plans to develop its own medicines
After a 4-yr decline that erased 65% from the value of Sun, Shanghvi is preparing to bounce back23-05-2019
Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditya Medisales Ltd22-05-2019
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia22-05-2019
Sun Pharmaceuticals may test a support at Rs 367
Shares of Sun Pharmaceutical Industries Limited fell as much as 7.2 per cent. The stock may test a support at Rs 366.88.The stock on Monday bounced ba16-05-2019
Today's picks: From Sun Pharma to L&T;, hot stocks to buy on Wednesday
Target prices, projected movements in terms of next session, unless otherwise stated15-05-2019
Sun Pharmaceutical Industries Ltd - 524715 - Clarification / Confirmation On News Item
This is with reference to your email(s) dated May 13, 2019 seeking clarification on the news item appeared at https://economictimes.indiatimes.com/markets/stocks/news/pharma-stocks-bleed-on-price-fixing-lawsuit-against-generic-drug-firms-in-us/articleshow/69308415.cms Sources dated May 13, 2019, titled "Pharma stocks bleed as US states file lawsuit against generic drug firms". We hereby submit our response as follows: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. (Brief Details of the litigation filed against our subsidiary company). Please note that in December 2016, the Attorney General of the State of Connecticut along with the Attorneys'' General of various other U.S. states had filed a lawsuit in Federal Court alleging that other generic pharmaceutical companies had violated antitrust laws by fixing prices and allocating customers . On 18 June 2018, an Amended Complaint to the above law suit was filed which added allegations as to certain of our subsidiaries and additional other generic companies. On 10 May 2019, the Attorney General of the State of Connecticut and additional Attorneys'' General of various U.S. states filed a second lawsuit in Federal Court similarly alleging that Taro Pharmaceuticals USA, Inc. (Taro), our subsidiary, and other companies operating in the U.S. generic drug industry had violated antitrust laws by fixing prices and allocating customers. Please note that our Company, Sun Pharmaceutical Industries Limited is not named in these litigations. As we understand from our concerned subsidiaries, in their belief, the allegations made in these lawsuits against them are without merit and our...14-05-2019
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to the announcement of financial results for the fourth quarter and full year ending March 31, 2019, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,14-05-2019
Investors desert healthcare counter; Sun Pharma plunges over 9%
Sun Pharma shares dived 9.39 per cent to close at Rs 396.85 on the BSE14-05-2019